Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study

Nov 30, 2020

Dimitrios A. Pappas, Christine Brittle, James E. Mossell III, Johanna B. Withers, Jeraldine Lim-Harashima & Joel M. Kremer Rheumatology International volume 41, pages585–593 (2021) Abstract: Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease...

Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis

Aug 14, 2020

Martin J. Bergman, Alan J. Kivitz, Dimitrios A. Pappas, Joel M. Kremer, Lixia Zhang, Anna Jeter & Johanna B. Withers Rheumatology and Therapy volume 7, pages775–792 (2020) Abstract: Introduction: The PrismRA® test identifies rheumatoid arthritis (RA) patients who...

Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients

Jul 22, 2020

Theodore Mellors, Johanna B. Withers, Asher Ameli, Alex Jones, Mengran Wang, Lixia Zhang, Helia N. Sanchez, Marc Santolini, Italo Do Valle, Michael Sebek, Feixiong Cheng, Dimitrios A. Pappas, Joel M. Kremer, Jeffery R. Curtis, Keith J. Johnson, Alif Saleh, Susan D....

Network-based prediction of drug combinations

Mar 13, 2019

Feixiong Cheng1,2,3,4,5, István A. Kovács1,2 & Albert-László Barabási1,2,6,7 Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating multiple complex diseases. Yet, our ability to identify and...

Use Of The PrismRA Test To Stratify Patients For Response To Anti-TNF Therapy In RA

Oct 30, 2018

Even though there are several different therapies with different mechanism of actions, 91% of patients are prescribed anti‑TNF therapy as first-line biologic DMARD treatment Published in The Journal of Precision Medicine Authors: Keith Johnson, PhD and Michael...

PrismRA: a personalized medicine test that accurately predicts rheumatoid arthritis patients who will not respond adequately to tumor necrosis factor inhibitors

Oct 22, 2018

Keith Johnson, Nancy Schoenbrunner and Dina Ghiassian 2018 ACR/ARHP Annual Meeting Abstract: Background: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism...